(AMN) AMN Healthcare - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 1.110m USD | Total Return: 16% in 12m

Healthcare Staffing, Workforce Technology, Language Services, Executive Search

Total Rating 54

Safety 75

Buy Signal 0.24

Medical Care Facilities
Industry Rotation: +10.9

Market Cap: 1.11B
Avg Turnover: 25.6M

Risk 3d forecast

Volatility68.4%

VaR 5^th Pctl11.0%

VaR vs Median-2.80%

Reward TTM

Sharpe Ratio0.47

Rel. Str. IBD77.7

Rel. Str. Peer Group73.2

Character TTM

Beta0.784

Beta Downside1.051

Hurst Exponent0.458

Drawdowns 3y

Max DD86.48%

CAGR/Max DD-0.41

CAGR/Mean DD-0.60

EPS (Earnings per Share)

EPS CAGR: -49.23%
EPS Trend: -92.9%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: -13.37%
Rev. Trend: -79.7%

Last SUE: 4.00
Qual. Beats: 3

Warnings

Interest Coverage Ratio -1.7 is critical

Choppy Below Avwap Earnings

Tailwinds

Pead, Confidence

Description: AMN AMN Healthcare

AMN Healthcare Services Inc. (NYSE: AMN) provides integrated workforce solutions and staffing services to healthcare facilities across the United States. Operating through three core segments-Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions-the company manages a diverse range of clinical staffing, including travel nursing, locum tenens, and allied health professionals such as therapists and technicians.

The business model relies on a mix of traditional staffing and technology-enabled services, including vendor management systems (VMS) and workforce optimization tools. This dual approach allows the company to address the structural labor shortages in the U.S. healthcare sector, where aging demographics and clinician burnout drive consistent demand for flexible staffing solutions.

In addition to clinical placement, AMN offers executive search, language services, and specialized teletherapy platforms for schools. The company operates under multiple recognized brands, including Nursefinders and B.E. Smith, to provide end-to-end human capital management for acute and sub-acute care hospitals.

Investors looking for deeper fundamental analysis may find it useful to evaluate these metrics on ValueRay. Given the cyclical nature of the healthcare staffing industry, monitoring shifts in hospital utilization rates is essential for assessing AMNs long-term revenue stability.

Headlines to Watch Out For

Declining pandemic-era premium labor demand pressures Nurse and Allied segment margins
Hospital budget constraints and cost-containment initiatives reduce temporary staffing utilization
Expansion of high-margin vendor management systems and language services diversifies revenue
Healthcare labor shortages and aging demographics sustain long-term demand for locum tenens
Rising interest rates and debt servicing costs impact net income and valuation

Piotroski VR‑10 (Strict) 5.0

Net Income: -32.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.27 > 0.02 and ΔFCF/TA 16.31 > 1.0
NWC/Revenue: 2.70% < 20% (prev 1.58%; Δ 1.12% < -1%)
CFO/TA 0.28 > 3% & CFO 739.2m > Net Income -32.4m
Net Debt (252.3m) to EBITDA (165.9m): 1.52 < 3
Current Ratio: 1.09 > 1.5 & < 3
Outstanding Shares: last quarter (39.1m) vs 12m ago 2.10% < -2%
Gross Margin: 27.63% > 18% (prev 0.29%; Δ 2.73k% > 0.5%)
Asset Turnover: 136.8% > 50% (prev 119.1%; Δ 17.69% > 0%)
Interest Coverage Ratio: -1.70 > 6 (EBITDA TTM 165.9m / Interest Expense TTM 40.0m)

Altman Z'' 2.35

A: 0.04 (Total Current Assets 1.14b - Total Current Liabilities 1.04b) / Total Assets 2.60b
B: 0.49 (Retained Earnings 1.27b / Total Assets 2.60b)
C: -0.03 (EBIT TTM -68.0m / Avg Total Assets 2.50b)
D: 0.67 (Book Value of Equity 1.27b / Total Liabilities 1.89b)
Altman-Z'' = 2.35 = BBB

Beneish M -3.50

DSRI: 0.75 (Receivables 442.2m/493.3m, Revenue 3.42b/2.85b)
GMI: 1.04 (GM 27.63% / 28.64%)
AQI: 0.78 (AQ_t 0.51 / AQ_t-1 0.65)
SGI: 1.20 (Revenue 3.42b / 2.85b)
TATA: -0.30 (NI -32.4m - CFO 739.2m) / TA 2.60b)
Beneish M = -3.50 (Cap -4..+1) = AA

What is the price of AMN shares? As of May 22, 2026, the stock is trading at USD 25.65 with a total of 754,057 shares traded.
Over the past week, the price has changed by -15.35%, over one month by +23.14%, over three months by +23.26% and over the past year by +16.01%.

Is AMN a buy, sell or hold? AMN Healthcare has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold AMN.

StrongBuy: 1
Buy: 2
Hold: 5
Sell: 1
StrongSell: 0

What are the forecasts/targets for the AMN price?

Analysts Target Price	28.1	9.7%

AMN Healthcare (AMN) - Fundamental Data Overview as of 18 May 2026

P/E Forward = 26.178
P/S = 0.3245
P/B = 1.5711
P/EG = 1.7113
Revenue TTM = 3.42b USD
EBIT TTM = -68.0m USD
EBITDA TTM = 165.9m USD
Long Term Debt = 767.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.80m USD (from shortTermDebt, last quarter)
Debt = 813.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.1m
Net Debt = 252.3m USD (calculated: Debt 813.1m - CCE 560.7m)
Enterprise Value = 1.36b USD (1.11b + Debt 813.1m - CCE 560.7m)
Interest Coverage Ratio = -1.70 (Ebit TTM -68.0m / Interest Expense TTM 40.0m)
EV/FCF = 1.93x (Enterprise Value 1.36b / FCF TTM 706.3m)
FCF Yield = 51.86% (FCF TTM 706.3m / Enterprise Value 1.36b)
FCF Margin = 20.66% (FCF TTM 706.3m / Revenue TTM 3.42b)
Net Margin = -0.95% (Net Income TTM -32.4m / Revenue TTM 3.42b)
Gross Margin = 27.63% ((Revenue TTM 3.42b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 26.76% (prev 26.08%)
Tobins Q-Ratio = 0.52 (Enterprise Value 1.36b / Total Assets 2.60b)
Interest Expense / Debt = 0.83% (Interest Expense 6.71m / Debt 813.1m)
Taxrate = 43.72% (48.3m / 110.5m)
NOPAT = -38.3m (EBIT -68.0m * (1 - 43.72%)) [loss with tax shield]
Current Ratio = 1.09 (Total Current Assets 1.14b / Total Current Liabilities 1.04b)
Debt / Equity = 1.14 (Debt 813.1m / totalStockholderEquity, last quarter 712.8m)
Debt / EBITDA = 1.52 (Net Debt 252.3m / EBITDA 165.9m)
Debt / FCF = 0.36 (Net Debt 252.3m / FCF TTM 706.3m)
Total Stockholder Equity = 651.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.30% (Net Income -32.4m / Total Assets 2.60b)
RoE = -4.98% (Net Income TTM -32.4m / Total Stockholder Equity 651.7m)
RoCE = -4.79% (EBIT -68.0m / Capital Employed (Equity 651.7m + L.T.Debt 767.1m))
RoIC = -3.81% (negative operating profit) (NOPAT -38.3m / Invested Capital 1.01b)
WACC = 5.24% (E(1.11b)/V(1.92b) * Re(8.74%) + D(813.1m)/V(1.92b) * Rd(0.83%) * (1-Tc(0.44)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 1.10%
[DCF] Terminal Value 84.79% ; FCFF base≈527.4m ; Y1≈457.6m ; Y5≈365.6m
[DCF] Fair Price = 278.7 (EV 11.06b - Net Debt 252.3m = Equity 10.81b / Shares 38.8m; r=6.0% [WACC]; 5y FCF grow -16.15% → 3.0% )
EPS Correlation: -92.87 | EPS CAGR: -49.23% | SUE: 4.0 | # QB: 1
Revenue Correlation: -79.72 | Revenue CAGR: -13.37% | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-06-30): EPS=0.19 | Chg30d=+165.54% | Revisions=N/A | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=+14.97% | Revisions=+0% | Analysts=9
EPS current Year (2026-12-31): EPS=2.66 | Chg30d=+30.78% | Revisions=+50% | GrowthEPS=+95.7% | GrowthRev=+19.1%
EPS next Year (2027-12-31): EPS=1.09 | Chg30d=-4.49% | Revisions=+0% | GrowthEPS=-59.2% | GrowthRev=-19.9%
[Analyst] Revisions Ratio: +50%